Biognosys AG
Biognosys AG
Oliver Rinner
Phone: +41-78 6644711
  • personalized medicine
  • crop protection
  • venture capital
  • proteomics

[ Download Photos ]

Tue, 01.11.2011
pts20111101005 Companies/Finance, Science/Technology
Pressbox Pressbox
Swiss proteomics leader got venture capital
Biognosys raises CHF 2.7m in Series A Financing
Oliver Rinner at a conference
Oliver Rinner at a conference
[ photos ]

Zurich (pts005/01.11.2011/09:15) - Biognosys, a Swiss ETH spin-off and pioneer in proteomics, attracted venture capital from experienced investors including Syngenta Ventures. Biognosys is the first company that can quantify every protein in biological samples fast and precisely. This is opening up entirely new options for precise diagnostics, personalized medicine and intelligent crop design.

Biognosys AG, the leader in targeted proteomics mass spectrometry founded in 2008 as an ETH Zurich spin off, announced today that it closed a CHF 2.7m Series A financing round with experienced venture capitalists. The round includes Hellmut Kirchner, co-founder of Germany's first venture fund TVM, Redalpine Capital I that had lead the seed round in 2009, ZKB start-up finance, venture arm of Cantonal Bank of Zurich, several private investors and Syngenta Ventures, corporate venture arm of agro-chemicals leader Syngenta. Subsequently, Ignacio Martinez will represent Syngenta Ventures at Biognosys' Board of Directors. The board is further strengthened by Hellmut Kirchner and by Harry Welten who has served as CFO for several listed biotech and pharmaceutical companies.

"The closing of this financing round reflects the investor's confidence in Biognosys team and our proprietary targeted proteomics technology," said Oliver Rinner, CEO of Biognosys. "Syngenta Ventures and the new investors are a great addition to our company. With the completion of this Series A round, we are well capitalized to bring Biognosys to the next phase of growth."

A wide range from personalized medicine to intelligent crop design
Biognosys delivers a technology platform for diagnostics, pharmaceutical, biotech and healthcare companies. Since operations started in 2010, the ETH spin-off has provided its Targeted Proteomics technology to identify and quantify proteins for companies such as Novartis, Pfizer, Integrated Diagnostics, and Philips. Recently Biognosys started exploring additional options in the field of intelligent crop design.

About Biognosys
Biognosys was spun off ETH Zurich in 2008 by ETH researchers Johan Malmström, Oliver Rinner, Philipp Antoni and Prof Ruedi Aebersold, who heads up the spin-off's scientific advisory board. In 2010 the team contributed to the sensational first mapping of the entire human proteome and secured all commercialization rights. Biognosys is a leader in the field of mass spectrometric protein measurements. Its next generation targeted proteomics platform, scheduled multiple reaction monitoring (MRM), can quantify proteins from any organism across variety of experimental conditions on a multiplexed scale. Targeted proteomics has a potential to fundamentally transform healthcare and other life science industries. Biognosys provides technology transfer, collaborative research, and supporting products for researchers that wish to achieve cost savings, and better products.

Oliver Rinner, PhD, CEO
BiognoSYS AG, Wagistrasse 25, CH-8952 Zurich-Schlieren, Switzerland
Mobile +41-78 6644711, Phone +41-44 7382040,

Submitter: Biognosys AG
Contact: Oliver Rinner
Phone: +41-78 6644711
Biognosys AG